BioNTech SE - ADR vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.21. The key difference: BioNTech SE - ADR is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BNTX | TLT | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | — |
52-Week High | $119.34 | $92.06 |
52-Week Low | $83.89 | $82.05 |
Enterprise Value | $6.60B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.29 with a slight 0.3% daily gain amid bearish technical signals. The ETF faces pressure from rising long-term Treasury yields, with the 30-year yield recently hitting 5.24% (The Motley Fool, 2026-08-02). Institutional interest persists as Ferguson Shapiro LLC acquired 37,900 shares (Defense World, 2026-08-10), but outflows and U.S. debt nearing $40 trillion weigh on sentiment.
Outlook remains cautious as higher yields and inflation concerns challenge TLT's performance. Opportunities exist for income-focused investors given dividend payments, but risks include Fed rate hike potential and escalating geopolitical tensions driving oil prices higher. The bearish technical setup suggests continued pressure unless bond market sentiment improves.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →